Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in ...

Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

These 10 defensive stocks supply investors with reliable earnings, and often dividends, when markets look uncertain. Maintaining independence and editorial freedom is essential to our mission of ...

Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Nektar Therapeutics ( (NKTR)) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its investors. Nektar Therapeutics is a clinical-stage ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...

Piper Sandler assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research note released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.